Prospective comparison of the therapeutic effect of teriparatide with that of combined vertebroplasty with antiresorptive agents for the treatment of new-onset adjacent vertebral compression fracture after percutaneous vertebroplasty

Osteoporosis International

Volumn 23, Issue 5, 2012, Pages 1613-1622

  Tseng, Y Y ^a,b   Su, C H ^c   Lui, T N ^a,b   Yeh, Y S ^a,b   Yeh, S H ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Adjacent vertebral fracture; Antiresorptive agent; Teriparatide .Vertebral compression fracture; Vertebroplasty

Indexed keywords

ALENDRONIC ACID; CALCIUM; PARATHYROID HORMONE[1-34]; RALOXIFENE; VITAMIN D;

AGE; ARTICLE; BONE STRENGTH; CLINICAL ARTICLE; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPIGASTRIC PAIN; FEMALE; HOT FLUSH; HUMAN; LEG CRAMP; LOW BACK PAIN; LUMBAR SPINE; MALE; MEDICAL HISTORY; NAUSEA; OSSIFICATION; OSTEOPOROSIS; PERCUTANEOUS VERTEBROPLASTY; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; VERTEBRA COMPRESSION; VERTEBRA COMPRESSION FRACTURE; VISUAL ANALOG SCALE; VITAMIN SUPPLEMENTATION;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COMBINED MODALITY THERAPY; FEMALE; FRACTURES, COMPRESSION; HUMANS; LOW BACK PAIN; LUMBAR VERTEBRAE; MALE; OSTEOPOROTIC FRACTURES; PAIN MEASUREMENT; PROSPECTIVE STUDIES; RECURRENCE; REOPERATION; SPINAL FRACTURES; TERIPARATIDE; TREATMENT OUTCOME; VERTEBROPLASTY;

EID: 84863626366     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1730-y     Document Type: Article

References (43)

1. Hall SE, Criddle RA, Comito TL, Prince RL (1999) A casecontrol study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture. Osteoporos Int 9:508-515 (Pubitemid 29348566)
2. Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010-2018 (Pubitemid 43867702)
3. Ploeg WT, Veldhuizen AG, The B, Sietsma MS (2006) Percutaneous vertebroplasty as a treatment for osteoporotic vertebral compression fractures: a systematic review. Eur Spine J 15:1749-1758 (Pubitemid 44900601)
4. Mudano AS, Bian J, Cope JU, Curtis JR, Gross TP, Allison JJ, Kim Y, Briggs D, Melton ME, Xi J, Saag KG (2009) Vertebroplasty and kyphoplasty are associated with an increased risk of secondary vertebral compression fractures: a population-based cohort study. Osteoporos Int 20:819-826
5. Boger A, Heini P, Windolf M, Schneider E (2007) Adjacent vertebral failure after vertebroplasty: a biomechanical study of low-modulus PMMA cement. Eur Spine J 16:2118-2125 (Pubitemid 350276084)
6. Trout AT, Kallmes DF, Kaufmann TJ (2006) New fractures after vertebroplasty: adjacent fractures occur significantly sooner. Ajnr 27:217-223 (Pubitemid 46939916)
7. Voormolen MH, Lohle PN, Juttmann JR, van der Graaf Y, Fransen H, Lampmann LE (2006) The risk of new osteoporotic vertebral compression fractures in the year after percutaneous vertebroplasty. J Vasc Interv Radiol 17:71-76 (Pubitemid 44392035)
8. Tseng YY, Yang TC, Tu PH, Lo YL, Yang ST (2009) Repeated and multiple new vertebral compression fractures after percutaneous transpedicular vertebroplasty. Spine 34:1917-1922
9. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541 (Pubitemid 26411651)
10. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Jama 282:637-645 (Pubitemid 29384151)
11. Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, Lindsay R, Mitlak BH (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 16:510-516
12. Marcus R, Wang O, Satterwhite J, Mitlak B (2003) The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 18:18-23 (Pubitemid 36008335)
13. Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, Jasqui S, Donley DW, Dalsky GP, Martin JS, Eriksen EF (2005) Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 20:1244-1253 (Pubitemid 40863814)
14. Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148 (Pubitemid 23261108)
15. Scott PJ, Huskisson EC (1977) Measurement of functional capacity with visual analogue scales. Rheumatol Rehabil 16:257-259 (Pubitemid 8220912)
16. Fukui M, Chiba K, Kawakami M, Kikuchi S, Konno S, Miyamoto M, Seichi A, Shimamura T, Shirado O, Taguchi T, Takahashi K, Takeshita K, Tani T, Toyama Y, Yonenobu K, Wada E, Tanaka T, Hirota Y (2007) Japanese Orthopaedic Association Back Pain Evaluation Questionnaire. Part 2. Verification of its reliability: The Subcommittee on Low Back Pain and Cervical Myelopathy Evaluation of the Clinical Outcome Committee of the Japanese Orthopaedic Association. J Orthop Sci 12:526-532 (Pubitemid 350190499)
17. Majumdar SR, Kim N, Colman I, Chahal AM, Raymond G, Jen H, Siminoski KG, Hanley DA, Rowe BH (2005) Incidental vertebral fractures discovered with chest radiography in the emergency department: prevalence, recognition, and osteoporosis management in a cohort of elderly patients. Arch Intern Med 165:905-909 (Pubitemid 40563237)
18. Buchbinder R, Osborne RH, Ebeling PR, Wark JD, Mitchell P, Wriedt C, Graves S, Staples MP, Murphy B (2009) A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. The New Engl J Med 361:557-568
19. Buchbinder R, Osborne RH, Kallmes D (2009) Vertebroplasty appears no better than placebo for painful osteoporotic spinal fractures, and has potential to cause harm. The Med J Australia 191:476-477
20. Kallmes DF, Comstock BA, Heagerty PJ, Turner JA, Wilson DJ, Diamond TH, Edwards R, Gray LA, Stout L, Owen S, Hollingworth W, Ghdoke B, Annesley-Williams DJ, Ralston SH, Jarvik JG (2009) A randomized trial of vertebroplasty for osteoporotic spinal fractures. The New Engl J Med 361:569-579
21. Lin CC, Shen WC, Lo YC, Liu YJ, Yu TC, Chen IH, Chung HW (2010) Recurrent pain after percutaneous vertebroplasty. Ajr 194:1323-1329
22. Nevitt MC, Chen P, Kiel DP, Reginster JY, Dore RK, Zanchetta JR, Glass EV, Krege JH (2006) Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. Osteoporos Int 17:1630-1637 (Pubitemid 44477623)
23. Nevitt MC, Chen P, Dore RK, Reginster JY, Kiel DP, Zanchetta JR, Glass EV, Krege JH (2006) Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int 17:273-280 (Pubitemid 43053592)
24. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762-1768 (Pubitemid 41138965)
25. Ulivieri FM (2007) Back pain treatment in post-menopausal osteoporosis with vertebral fractures. Aging Clin Exp Res 19:21-23
26. Genant HK, Halse J, Briney WG, Xie L, Glass EV, Krege JH (2005) The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin 21:1027-1034 (Pubitemid 41032691)
27. Polikeit A, Nolte LP, Ferguson SJ (2003) The effect of cement augmentation on the load transfer in an osteoporotic functional spinal unit: finite-element analysis. Spine 28:991-996 (Pubitemid 36583327)
28. Nouda S, Tomita S, Kin A, Kawahara K, Kinoshita M (2009) Adjacent vertebral body fracture following vertebroplasty with polymethylmethacrylate or calcium phosphate cement: biomechanical evaluation of the cadaveric spine. Spine 34:2613-2618
29. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. The New Engl J Med 337:1641-1647 (Pubitemid 27510100)
30. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. The New Engl J Med 350:1189-1199 (Pubitemid 38339363)
31. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB (2002) A randomized doubleblind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:4528-4535 (Pubitemid 35247036)
32. Wasnich RD, Miller PD (2000) Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231-236 (Pubitemid 32268819)
33. Hernandez CJ, Beaupre GS, Marcus R, Carter DR (2001) A theoretical analysis of the contributions of remodeling space, mineralization, and bone balance to changes in bone mineral density during alendronate treatment. Bone 29:511-516 (Pubitemid 33124292)
34. Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH (2006) Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 21:1785-1790 (Pubitemid 46141234)
35. Glover SJ, Eastell R, McCloskey EV, Rogers A, Garnero P, Lowery J, Belleli R, Wright TM, John MR (2009) Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 45:1053-1058
36. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF (2003) Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932-1941 (Pubitemid 37377441)
37. Chen P, Miller PD, Recker R, Resch H, Rana A, Pavo I, Sipos AA (2007) Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res 22:1173-1180 (Pubitemid 351339699)
38. Blick SK, Dhillon S, Keam SJ (2008) Teriparatide: a review of its use in osteoporosis. Drugs 68:2709-2737
39. Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ (2006) Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 54:782-789 (Pubitemid 44030200)
40. Abrahamsen B, Hansen TB, Jensen LB, Hermann AP, Eiken P (1997) Site of osteodensitometry in perimenopausal women: correlation and limits of agreement between anatomic regions. J Bone Miner Res 12:1471-1479 (Pubitemid 27375391)
41. Miller PD, Zapalowski C, Kulak CA, Bilezikian JP (1999) Bone densitometry: the best way to detect osteoporosis and to monitor therapy. J Clin Endocrinol Metab 84:1867-1871 (Pubitemid 30647000)
42. Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH (2005) Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20:1507-1513 (Pubitemid 41243539)
43. Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster JY, Stepan JJ, Myers SL, Mitlak BH (2004) Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164:2024-2030 (Pubitemid 39390560)